Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction

American Heart Journal

Volumn 197, Issue , 2018, Pages 43-52

  Sullivan, Lonnie T ^a,c   Randolph, Tiffany ^b   Merrill, Peter ^c   Jackson, Larry R ^a,c   Egwim, Chidiebube ^a   Starks, Monique A ^c   Thomas, Kevin L ^a,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Center for Women s Healthcare and Maternal Fetal Care   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLACK PERSON; CLINICAL OUTCOME; CONTROLLED STUDY; EMBASE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HUMAN; INFORMATION RETRIEVAL; MEDLINE; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; VULNERABLE POPULATION; DIAGNOSIS; DRUG THERAPY; ETHNOLOGY; HEART FAILURE; HEART STROKE VOLUME; HEART VENTRICLE FUNCTION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS AND NUMERICAL DATA;

AFRICAN CONTINENTAL ANCESTRY GROUP; DEFIBRILLATORS, IMPLANTABLE; DRUG THERAPY; HEART FAILURE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE VOLUME; VENTRICULAR DYSFUNCTION;

EID: 85039981232     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2017.10.025     Document Type: Review

References (61)

1. Moore, R.D., Stanton, D., Gopalan, R., Chaisson, R.E., Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med 330:11 (1994), 763–768.
2. Bach, P.B., Cramer, L.D., Warren, J.L., Begg, C.B., Racial differences in the treatment of early-stage lung cancer. N Engl J Med 341:16 (1999), 1198–1205.
3. Vaccarino, V., Rathore, S.S., Wenger, N.K., et al. Sex and racial differences in the management of acute myocardial infarction, 1994 through 2002. N Engl J Med 353:7 (2005), 671–682.
4. Howard, G., Lackland, D.T., Kleindorfer, D.O., et al. Racial differences in the impact of elevated systolic blood pressure on stroke risk. JAMA Intern Med 173:1 (2013), 46–51.
5. Bahrami, H., Kronmal, R., Bluemke, D.A., et al. Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med 168:19 (2008), 2138–2145.
6. Bibbins-Domingo, K., Pletcher, M.J., Lin, F., et al. Racial differences in incident heart failure among young adults. N Engl J Med 360:12 (2009), 1179–1190.
7. Ziaeian, B., Fonarow, G.C., Epidemiology and aetiology of heart failure. Nat Rev Cardiol 13:6 (2016), 368–378.
8. Heidenreich, P.A., Albert, N.M., Allen, L.A., et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 6:3 (2013), 606–619.
9. Sharma, A., Colvin-Adams, M., Yancy, C.W., Heart failure in African Americans: disparities can be overcome. Cleve Clin J Med 81:5 (2014), 301–311.
10. Kishi, S., Reis, J.P., Venkatesh, B.A., et al. Race-ethnic and sex differences in left ventricular structure and function: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. J Am Heart Assoc, 4(3), 2015, e001264.
11. He, J., Ogden, L.G., Mazzano, L.A., et al. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 161:7 (2001), 996–1002.
12. Kenchaiah, S., Narula, J., Vasan, R.S., Risk factors for heart failure. Med Clin North Am 88:5 (2004), 1145–1172.
13. Yancy, C.W., Heart failure in African Americans. Am J Cardiol 96:7B (2005), 3i–12i.
14. Heiat, A., Gross, C.P., Krumholz, H.M., Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 162:15 (2002), 1682–1688.
15. Zhang, T., Tsang, W., Wijeysundera, H.C., Ko, D.T., Reporting and representation of ethnic minorities in cardiovascular trials: a systematic review. Am Heart J 166:1 (2013), 52–57.
16. Downing, N.S., Shah, N.D., Neiman, J.H., Aminawung, J.A., Krumholz, H.M., Ross, J.S., Participation of the elderly, women, and minorities in pivotal trials supporting 2011–2013 U.S. Food and Drug Administration approvals. Trials, 17, 2016, 199.
17. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:16 (2013), e147–239.
18. Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Card Fail 23:8 (2017), 628–651.
19. Colby, S.L., Ortman, J.M., Projections of the size and composition of the U.S. population: 2014 to 2060. 2015, US Census Bureau, 25–1143.
20. Freedman, L.S., Simon, R., Foulkes, M.A., et al. Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993—the perspective of NIH clinical trialists. Control Clin Trials 16:5 (1995), 277–285 [discussion 286–9, 293–309].
21. Thiers, F.A., Sinskey, A.J., Berndt, E.R., Trends in the globalization of clinical trials. Nat Rev Drug Discov 7:1 (2008), 13–14.
22. Glickman, S.W., McHutchison, J.G., Peterson, E.D., et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 360:8 (2009), 816–823.
23. Yancy, C.W., Abraham, W.T., Albert, N.M., et al. Quality of care of and outcomes for African Americans hospitalized with heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry. J Am Coll Cardiol 51:17 (2008), 1675–1684.
24. Thomas, K.L., Hernandez, A.F., Dai, D., et al. Association of race/ethnicity with clinical risk factors, quality of care, and acute outcomes in patients hospitalized with heart failure. Am Heart J 161:4 (2011), 746–754.
25. Officers, A, A.C.R.G.T.A. Coordinators for the, and T, Lipid-lowering treatment to prevent heart attack, major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:23 (2002), 2981–2997.
26. SPRINT Research Group, A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:22 (2015), 2103–2116.
27. Taylor, A.L., Ziesche, S., Yancy, C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351:20 (2004), 2049–2057.
28. Beta-Blocker Evaluation of Survival Trial, I, A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 344:22 (2001), 1659–1667.
29. Cohn, J.N., Archibald, D.G., Ziesche, S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314:24 (1986), 1547–1552.
30. Cohn, J.N., Johnson, G., Ziesche, S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325:5 (1991), 303–310.
31. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med, 325(5), 1991, 293–302.
32. Solvd Investigators, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327:10 (1992), 685–691.
33. Packer, M., Bristow, M.R., Cohn, J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:21 (1996), 1349–1355.
34. Digitalis Investigation, G, The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:8 (1997), 525–533.
35. Pitt, B., Segal, R., Martinez, F.A., et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349:9054 (1997), 747–752.
36. Packer, M., Poole-Wilson, P.A., Armstrong, P.W., et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 100:23 (1999), 2312–2318.
37. Pitt, B., Zannad, F., Remme, W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:10 (1999), 709–717.
38. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 353(9169), 1999, 2001–2007.
39. Pitt, B., Poole-Wilson, P.A., Segal, R., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II. Lancet 355:9215 (2000), 1582–1587.
40. Cohn, J.N., Tognoni, G., I. Valsartan Heart, Failure Trial, A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:23 (2001), 1667–1675.
41. Packer, M., Coats, A.J.S., Fowler, M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:22 (2001), 1651–1658.
42. Moss, A.J., Zareba, W., Hall, W.J., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:12 (2002), 877–883.
43. Granger, C.B., McMurray, J.J.V., Yusuf, S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:9386 (2003), 772–776.
44. McMurray, J.J.V., Ostergren, J., Swedberg, K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362:9386 (2003), 767–771.
45. Bristow, M.R., Saxon, L.A., Boehmer, J., et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:21 (2004), 2140–2150.
46. Bardy, G.H., Lee, K.L., Mark, D.B., et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:3 (2005), 225–237.
47. Linde, C., Abraham, W.T., Gold, M.R., Sutton, M., Ghio, S., Daubert, C., Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 52:23 (2008), 1834–1843.
48. Fox, K., Ford, I., Steg, P.G., Tendera, M., Ferrari, R., Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372:9641 (2008), 807–816.
49. Moss, A.J., Hall, W.J., Cannom, D.S., et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361:14 (2009), 1329–1338.
50. Tang, A.S.L., Wells, G.A., Talajic, M., et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med 363:25 (2010), 2385–2395.
51. Swedberg, K., Komajda, M., Böhm, M., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376:9744 (2010), 875–885.
52. Zannad, F., McMurray, J.J.V., Krum, H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:1 (2011), 11–21.
53. McMurray, J.J.V., Packer, M., Desai, A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:11 (2014), 993–1004.
54. Carson, P., Ziesche, S., Johnson, G., Cohn, J.N., Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5:3 (1999), 178–187.
55. Dries, D.L., Exner, D.V., Gersh, B.J., Cooper, H.A., Carson, P.E., Domanski, M.J., Racial differences in the outcome of left ventricular dysfunction. N Engl J Med 340:8 (1999), 609–616.
56. Yancy, C.W., Fowler, M.B., Colucci, W.S., et al. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 344:18 (2001), 1358–1365.
57. Mathew, J., Wittes, J., McSherry, F., et al. Racial differences in outcome and treatment effect in congestive heart failure. Am Heart J 150:5 (2005), 968–976.
58. Wedel, H., DeMets, D., Deedwania, P., et al. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial. Am Heart J 142:3 (2001), 502–511.
59. Eichhorn, E.J., Bristow, M.R., The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med 2:1 (2001), 20–23.
60. Vorobiof, G., Goldenberg, I., Moss, A.J., Zareba, W., McNitt, S., Effectiveness of the implantable cardioverter defibrillator in blacks versus whites (from MADIT-II). Am J Cardiol 98:10 (2006), 1383–1386.
61. Mitchell, J.E., Hellkamp, A.S., Mark, D.B., et al. Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 155:3 (2008), 501–506.